Adverum Biotechnologies, Inc. - Common Stock (ADVM)
3.4300
+0.00 (0.00%)
NASDAQ · Last Trade: Apr 15th, 1:34 AM EDT
Detailed Quote
Previous Close
3.430
Open
3.430
Bid
3.230
Ask
3.730
Day's Range
3.260 - 3.586
52 Week Range
3.070 - 12.09
Volume
140,269
Market Cap
336.57M
PE Ratio (TTM)
0.7743
EPS (TTM)
4.4
Dividend & Yield
N/A (N/A)
1 Month Average Volume
163,202
Chart
About Adverum Biotechnologies, Inc. - Common Stock (ADVM)
Adverum Biotechnologies is a biotechnology company focused on developing innovative gene therapies to treat ocular diseases and other serious conditions. The company leverages its proprietary technology to create targeted and long-lasting treatments that aim to improve patient outcomes. Adverum's research and development efforts are centered around utilizing viral vectors to deliver genetic material to affected cells, potentially addressing the underlying causes of diseases and offering new hope for patients with limited treatment options. Through collaboration with scientific and medical communities, Adverum seeks to advance its pipeline of therapies and contribute to the evolving field of genetic medicine. Read More
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (“Adverum” or “the Company”) (NASDAQ: ADVM) for violations of the securities laws.
NEW YORK, April 12, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (“Adverum” or the “Company”) (NASDAQ: ADVM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Adverum Biotechnologies presented 26-week interim data from the LUNA Phase 2 trial for Ixo-vec in wet AMD. The analysis showed significant reductions in anti-VEGF injections and positive visual outcomes.
Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and board changes. Lifecore Biomedical shares dipped 31.7% to $4.91 on Wednesday.
Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction.
Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS guidance below estimates.
Adverum will sell the shares at a price per share of $1.20, representing a premium of approximately 20% to its stock's 30-day volume-weighted average price, and the financing is expected to close on Feb. 8. Adverum anticipates the gross proceeds from the private placement to be approximately $127.5 million, before deducting any offering related expenses and are expected to be sufficient to fund the current operating plan into late 2025.
Adverum Biotechnologies Inc (NASDAQ: ADVM) revealed updated data from the OPTIC extension study of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in patients with wet AMD during the Retina Subspecialty Day at the American Academy of Ophthalmology
